Germanium and Cancer Treatment
Germanium is present in all living plant and animal matter in micro-trace quantities. Its therapeutic attributes include immuno-enhancement, oxygen enrichment, free radical scavenging, analgesia, and heavy metal detoxification. Toxicological studies document Germanium’s rapid absorption and elimination from the body, and its safety.
Clinical use in private practices for more than a decade has demonstrated Germanium’s efficacy in treating a wide range of serious afflictions, including many types of cancer, arthritis, and senile osteoporosis. Germanium’s anti-viral and immunological properties include the induction of interferon, macrophages, T-suppressor cells, and augmentation of natural killer cell activity.
How Does Germanium Treatment Function?
Organica Germanium benefits as a naturally occurring element that has been studied for its potential to treat cancer and other conditions. At Sunridge Medical, we are dedicated to studying germanium and its potential therapeutic uses in the fight against cancer. We believe germanium may offer a safe and effective option for those looking for alternative treatments beyond traditional chemotherapy or radiation therapies.
Our research centers around germanium’s ability to deliver oxygen directly to cells and how this can potentially help improve outcomes in patients with various forms of cancer.
We strive to provide comprehensive germanium-based solutions to help those suffering from cancer. With our cutting-edge germanium treatments, we are committed to improving the lives of our patients and helping them reach their optimum health.
References on Germanium Cancer Treatment
Goodman S. Therapeutic effects of organic germanium. Med Hypotheses. 1988 Jul;26(3):207-15. doi: 10.1016/0306-9877(88)90101-6. PMID: 3043151. https://pubmed.ncbi.nlm.nih.gov/3043151/
Germanium is present in all living plant and animal matter in micro-trace quantities. Its therapeutic attributes include immuno-enhancement, oxygen enrichment, free radical scavenging, analgesia and heavy metal detoxification.
Toxicological studies document Germanium’s rapid absorption and elimination from the body, and its safety. Clinical trials and use in private practices for more than a decade have demonstrated Germanium’s efficacy in treating a wide range of serious afflictions, including cancer, arthritis and senile osteoporosis.
Germanium’s anti-viral and immunological properties, including the induction of interferon, macrophages, T-suppressor cells and augmentation of natural killer cell activity, suggest its possible efficacy in treating and/or preventing AIDS.
Slavik M, Blanc O, Davis J. Spirogermanium: a new investigational drug of novel structure and lack of bone marrow toxicity. Invest New Drugs. 1983;1(3):225-34. doi: 10.1007/BF00208894. PMID: 6678870.
Abstract: Spirogermanium (NSC 192965) is a new metallic investigational anticancer drug of novel heterocyclic structure. Although its mode of action has not been fully elucidated, it appears that spirogermanium is not a phase or cell cycle specific drug and inhibits DNA, RNA and protein synthesis, the protein synthesis being the most susceptible to this agent. Spirogermanium has shown cytotoxic activity in vitro against several human tumor cell lines at concentrations (1 micrograms/ml) that were also found toxic to the cultured rat neurons.
Although spirogermanium has no effect on normal bone marrow colony forming cells in mice, dogs, or man, it has revealed cytotoxic activity in vitro against human myeloid leukemia cell line K 562 at clinically achievable concentrations. These in vitro findings, indicating selective cytotoxic activity against leukemic cells suggest this drug as a candidate for clinical studies in acute and chronic leukemias.
Spirogermanium has revealed activity in vivo against intraperitoneally implanted Walker 256 sarcoma, 13762 mammary adenocarcinoma, and 11095 prostatic carcinoma in rats, but no antitumor activity in vivo was found in the murine tumors used in the past by the NCI screen (L 1210 and P 388 leukemia, B 16 melanoma, Lewis lung carcinoma). Spirogermanium is remarkable for its lack of bone marrow toxicity confirmed in preclinical toxicology and clinical studies; moderate, predictable, and reversible CNS toxicity is dose-limiting.
Activity in malignant lymphoma, ovarian cancer, breast cancer, large bowel cancer, and prostatic cancer was reported in the clinical studies. The drug is currently under clinical investigation against the wide spectrum of solid tumors and malignant lymphomas. The dose of 80-120 mg/m2, given by 60′ infusion three times a week, is currently used and tolerated in Phase II clinical studies.
The recently introduced five days continuous infusion schedule has been also under clinical investigation and the doses of 250-300 mg/m2/day are recommended for Phase II studies.
Of interest are results reported in this paper of spirogermanium in vitro preferential activity against the resistant strains of Plasmodium falciparum at clinically achievable concentrations suggesting this drug as a possible new antimalarial agent of novel structure.
Germanium and Immunostimulation in Cancer
Germanium has long been considered a therapeutic agent with anticancer, anti-tumor, anti-aging, antiviral, and anti-inflammatory effects. Numerous clinical studies have explored the promising therapeutic effects of organic germanium on cancer, arthritis, and senile osteoporosis. The immune activation property of organic germanium is considered the foundation of its various therapeutic effects. However, previous human clinical studies investigating immune activation with organic germanium compounds have certain limitations, as some studies did not strictly follow a randomized, double-blind, placebo-controlled design.
To build a more clinically substantiated foundation for the mechanism underlying its immunostimulation, treatment and during dimethylhydrazinewe structured by far the most rigorous clinical study to date with a group of 130 human subjects to examine changes in immune profiles following germanium supplementation. We used Bio-Germanium, an organic germanium compound naturally synthesized via a yeast fermentation process.
An 8-week randomized, double-blind, treatment and during dimethylhydrazine placebo-controlled study was conducted with 130 subjects with leukocyte counts of 4–8 (×103/μL) divided into the Bio-Germanium group and the placebo group. Anthropometric measurements; blood collection; biochemical analysis; urinalysis; natural killer cell activity, cytokine, and immunoglobulin assays were conducted.
Results showed the Bio-Germanium group exhibited NK cell activity increases at effector cell: target cell (E:T) ratios of 50:1, 10:1, 5:1, and 2.5:1 (12.60±32.91%, 10.19±23.88%, 9.28±16.49%, and 7.27±15.28%, respectively), but the placebo group showed decreases (P<0.01). The difference in the IgG1 change from baseline to follow-up between the Bio-Germanium and placebo groups was significant (P = 0.044).
Our results and earlier clinical study of Bio-Germanium confirm that Bio-Germanium acts as an effective immunostimulant by increasing the cytotoxicity of NK cells and activating immunoglobulin, B cells, and tumor necrosis factor (TNF)-α (P<0.05). As we have added newly discovered clinical findings for germanium’s immunostimulation mechanism, we believe Bio-Germanium is a highly promising therapeutic agent and should certainly be further explored for potential development opportunities in immunotherapy.